Digital Self-Management Intervention Paths for Early Breast Cancer Patients: Results of a Pilot Study.

Background: Despite excellent prognosis of early breast cancer, the patients face problems related to decreased quality of life and mental health. There is a need for easily available interventions targeting modifiable factors related to these problems. The aim of this study was to test the use of a new digital supportive intervention platform for early breast cancer patients.

Interoception and body image in breast cancer patients: a mindfulness-based stress reduction protocol.

Breast cancer impairs physical and psychological well-being, even some years after treatments. Oncological treatments can strongly affect the body due to scars and breast(s) removal, for example, increasing symptoms of anxiety and depression. Psychological studies are effective in improving breast cancer survivors' emotions and behaviors through several approaches to interventions.

Results of the Italian cross-sectional web-based survey "Nutrition and breast cancer, what would you like to know?" An attempt to collect and respond to patients' information needs, through social media.

Introduction: Several studies have demonstrated that, following a breast cancer (BC) diagnosis, patients are eager to obtain information on cancer and nutrition, in order to ameliorate both their quality of life (QoL) and disease outcome. To avoid BC survivors to get wrong information from unreliable sources, healthcare providers need to be aware of patients' needs, to guide them toward optimal nutrition recommendations, aimed at preventing tumor recurrence and increasing survival rates.

Material And Methods: The cross-sectional web-based survey "Nutrition and breast cancer, what would you like to know?" has been conceived and conducted, in Italy, between the 2nd and the 25th of June 2023.

EV20/Omomyc: A novel dual MYC/HER3 targeting immunoconjugate.

MYC is one of the most important therapeutic targets in human cancer. Many attempts have been made to develop small molecules that could be used to curb its activity in patients, but most failed to identify a suitable direct inhibitor. After years of preclinical characterization, a tissue-penetrating peptide MYC inhibitor, called Omomyc, has been recently successfully used in a Phase I dose escalation study in late-stage, all-comers solid tumour patients.

Correction: Counterfactual thinking in psychiatric and neurological diseases: A scoping review.

[This corrects the article DOI: 10.1371/journal.pone.